Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab in Relapsed/Progressive DLBCL
NCT00622388Phase 2Completed
- Sponsor
- GSK
- Start
- Dec 2007
- Primary completion
- May 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ofatumumab in diffuse large B-cell lymphoma (DLBCL), sponsored by GSK. Started Dec 2007; status: completed.
02
Drugs
ofatumumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00622388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00622388.